Dr. Yee graduated from the American University of the Caribbean School of Medicine in 1983. He works in Kailua, HI and specializes in Cardiovascular Disease. Dr. Yee is affiliated with Castle Medical Center.
Forestridge Elementary School Dallas TX 1976-1977, Zion Lutheran School Dallas TX 1977-1983, Merriman Park Elementary School Dallas TX 1983-1985, Forest Meadow Junior High School Dallas TX 1985-1988
Subang JayaManagement Consultant at Local Malaysian incorpora... I am experienced and well-connected in the following areas:
1. Higher Education Industry in Malaysia
2. Franchising and Licensing system locally in... I am experienced and well-connected in the following areas:
1. Higher Education Industry in Malaysia
2. Franchising and Licensing system locally in Malaysia as well as international scenerio.
3. Corporate Training in the areas of personal development, motivation, stress management, team...
Jefferies' Michael Yee joins 'Closing Bell' to discuss biotech stocks,...
Duration:
2m 29s
Biotech will face challenges this year, says ...
Turn to CNBC TV for the latest stock market news and analysis. From ma...
Duration:
2m 46s
Jefferies Michael Yee explains why he is bull...
Turn to CNBC TV for the latest stock market news and analysis. From ma...
Duration:
5m
Biotech stocks have been overlooked for the p...
Michael Yee, Jefferies managing director, joins 'Power Lunch' to break...
Duration:
4m 18s
Jefferies' Michael Yee explains his top biote...
Turn to CNBC TV for the latest stock market news and analysis. From ma...
Duration:
2m 57s
Jefferies' Michael Yee on heart inflammation ...
Turn to CNBC TV for the latest stock market news and analysis. From ma...
Duration:
4m 19s
Googleplus
Michael Yee
Work:
Contac Services - Web Storefront Coordinator (2009-2012) Global Aid Network - Graphic Designer (2005-2009) Global Aid Network - Graphic Design Instructor (2004-2005)
About:
Project Manager Specializing in Creative, Communication, and Printing Fields Print Designer North Korea Analyst
Tagline:
Print Professional - Open to Opportunities. Specializing in Project Management & Client Relations
Michael Yee
Work:
Amazon.com - Sr. User Experience Designer (2010)
Education:
North Carolina State University - BS Computer Science
Tagline:
You cannot achieve the impossible without attempting the absurd.
Michael Yee
Work:
Amway (2011)
Education:
Sunway University - Bachelor of Science (Hons) Business Studies
Michael Yee
Work:
SOLO8 - Owner (2012)
Michael Yee
Work:
Qantas - Implementation Analyst (2011-2013)
Michael Yee
Education:
Seneca College - Broadcasting - Radio, Ryerson University - Business Management
Michael Yee
About:
Copywriter, Photographer, Senior Consultant of Feeling Good Hubâ„¢, a social media company for enhancing wellness, prosperity and community building.
"We see modest perceived headwind to vaccine stocks such as MRNA (Moderna) if the market thinks people will be less afraid of COVID-19 and less inclined to get vaccines, if there is a simple pill that can treat COVID-19," Jefferies analyst Michael Yee said in a client note.
Date: Oct 02, 2021
Category: More news
Source: Google
Whether COVID-19 boosters get approved or not, Pfizer and Moderna have already made their money
osting will ultimately be offered to all who want it, in part, to avoid inequalities between the 1.1 [million] people who have already received a booster (and more people continue to seek boosters out there) and those who may want one but cannot get one, Jefferies analyst Michael Yee said Sept. 15.
Date: Sep 22, 2021
Category: More news
Source: Google
Covid-19 Booster-Shot Access May Be More Limited, CDC Committee Signals
In a separate note, Jefferies analyst Michael Yee wrote that ACIP was taking a conservative approach. ACIP still appears to be hesitant on whether [additional] doses are needed despite waning antibodies and increasing infections, Yee wrote. We think the ACIP could be leaning toward just a narrow
Date: Aug 31, 2021
Category: More news
Source: Google
US backs waiving intellectual property rules on vaccines
Michael Yee, a Jefferies Group biotech analyst, wrote to investors that the key access issues for developing countries arent patents or price, but an inadequate supply of the materials needed and the know-how to produce the vaccines and keep quality high which one of Johnson & Johnsons contr
Jefferies analyst Michael Yee thinks that mRNA-1273 could generate annual sales topping $5 billion if it's approved. That estimate doesn't seem unrealistic, considering the overall market opportunity for COVID-19 vaccines. But only looking at Moderna's prospects for mRNA-1273 shortchanges the biotec
Date: Jul 23, 2020
Category: More news
Source: Google
3 Coronavirus Stocks That Could Make You a Fast Fortune
plans to kick off a phase 3 study of mRNA-1273 on July 27. If all goes well, the company could be on a fast path to winning FDA Emergency Use Authorization and full approval. Jefferies analyst Michael Yee thinks that Moderna's COVID=19 vaccine could make over $5 billion per year if it wins approval.
Date: Jul 19, 2020
Category: More news
Source: Google
Moderna jumps as analyst sees over US$5B vaccine sales
The more than 230 per centsurge for the stock since the start of the year has split Wall Street as to what will happen or if the vaccine will even work, and investors are hugely divided on valuation, analyst Michael Yee said, initiating the stock at a buy.
Date: Jul 13, 2020
Category: More news
Source: Google
Gilead Sciences Stock Drops as Latest Data on Coronavirus Drug Not Good Enough
As Jefferies Michael Yee notes, consensus already understands remdesivir is not a silver bullet. That said, with a statistically significant positive (but modest) result, bulls and bears are likely to be able to pull what they like from the report.